PRTCY (PureTech Health) Stock Based Compensation: $8.22 Mil (TTM As of Dec. 2025)


PRTCY PureTech Health PLC PRTCY
62 GF Score
Price $17.54
GF Value $70.09
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is PureTech Health Stock Based Compensation?

PureTech Health PRTCY +1.49% 62 Stock Based Compensation is $8.22 Mil as of Dec. 2025. GuruFocus rates PRTCY with a GF Score™ of 62/100 and a GF Value™ of $70.09 (Possible Value Trap). The stock has 4 warning signs investors should review.

PureTech Health's Stock Based Compensation for the six months ended in Dec. 2025 was $3.49 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $8.22 Mil.

PureTech Health Stock Based Compensation Related Terms

PureTech Health Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for PureTech Health's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PureTech Health Stock Based Compensation Chart

PureTech Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.95 14.70 4.42 22.85 8.22

PureTech Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.16 4.65 18.20 4.73 3.49
PRTCY
62GF Score
PureTech Health PLC PRTCY
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PureTech Health Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $8.22 Mil.

What does a Stock Based Compensation of $8.22 Mil mean?
PureTech Health (PRTCY) has a Stock Based Compensation of $8.22 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for PureTech Health and its competitors.
Is PureTech Health's Stock Based Compensation too high?
PureTech Health's current Stock Based Compensation is $8.22 Mil. Overall, PureTech Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Stock Based Compensation compare to VRTX and REGN?
PureTech Health's Stock Based Compensation of $8.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for PureTech Health and its competitors. PureTech Health's current Stock Based Compensation is $8.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (PRTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $70.09, compared to a current price of $17.54 — trading 75% below its estimated fair value. The current Stock Based Compensation is $8.22 Mil. PureTech Health's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For PureTech Health (PRTCY), the current Stock Based Compensation is $8.22 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PureTech Health (PRTCY) Overvalued in 2026?

Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued. The current stock price of $17.54 is trading 75% below its estimated GF Value™ of $70.09. GuruFocus considers PureTech Health to be Possible Value Trap.

Key valuation signals for PRTCY:

  • Stock Based Compensation: $8.22 Mil
  • GF Value™: $70.09 vs. price of $17.54 (75% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the PRTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PureTech Health Business Description

Address 6 Tide Street, Suite 400, Boston, MA, USA, 02210
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score

Get the complete analysis for PRTCY

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.54
Price
$70.09
GF Value